Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224650 · ClinicalTrials.gov registry record
Validation of Novel Predictive Score for Patients With Spinal Metastases
A clinical trial of Spinal Metastases, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 219
- Enrollment target
- 1
- Study location
NCT03224650: Completed study of Spinal Metastases, sponsored by Brigham and Women's Hospital.
NCT03224650 is a study of Spinal Metastases that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 219 participants, above the 74-participant average among 5 other Spinal Metastases trials with a reported enrollment target (196% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03224650, a study of Spinal Metastases, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 219 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are prospectively validating a prognostic clinical tool that uses a patient's modified Bauer grade, ambulatory status, and pre-operative serum albumin to predict survival, post-treatment morbidity, and functional outcomes in patients with metastatic disease involving the spine.
Primary Outcome
Mortality is documented using date of death in medical record
Conditions Studied
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2022-01-31 |
What the finished NCT03224650 record still lists
NCT03224650 is an observational study that tracks outcomes without assigning an intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, above the 74-participant average among 5 other Spinal Metastases trials with a reported enrollment target (196% higher).
The record links to 1 condition, with Spinal Metastases appearing as the primary indexed condition, and to 0 interventions.
NCT03224650 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03224650 about?
NCT03224650 is a clinical study titled "Validation of Novel Predictive Score for Patients With Spinal Metastases". The investigators are prospectively validating a prognostic clinical tool that uses a patient's modified Bauer grade, ambulatory status, and pre-operative serum albumin to predict survival, post-treatment morbidity, and functional outcomes in patients with metastatic disease involving the spine.
What is the current status of trial NCT03224650?
This trial is currently completed. The enrollment target is 219 participants. The study started on 2017-07-01. Estimated completion is 2022-01-31.
What conditions does trial NCT03224650 study?
This clinical trial studies the following conditions: Spinal Metastases.
Who is sponsoring clinical trial NCT03224650?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224650 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
D20054;LITT for Spine Tumors
RECRUITING · NA
-
Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases
RECRUITING · Phase 3
-
A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy
ACTIVE NOT RECRUITING
-
Intra-arterial Chemotherapy for Spinal Metastases
COMPLETED · Phase 1
-
Stereotactic Body Radiotherapy for Spine Tumors
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT05907980 · 219 participants · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI